- Home
- HPH vs IPSC Comparison
HPH vs IPSC Comparison
Compare HPH & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPH
- IPSC
- Stock Information
- Founded
- HPH 2010
- IPSC 2019
- Country
- HPH China
- IPSC United States
- Employees
- HPH N/A
- IPSC N/A
- Industry
- HPH
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- HPH
- IPSC Health Care
- Exchange
- HPH NYSE
- IPSC Nasdaq
- Market Cap
- HPH 137.1M
- IPSC 149.1M
- IPO Year
- HPH 2019
- IPSC 2021
- Fundamental
- Price
- HPH $0.34
- IPSC $1.22
- Analyst Decision
- HPH
- IPSC Strong Buy
- Analyst Count
- HPH 0
- IPSC 4
- Target Price
- HPH N/A
- IPSC $13.00
- AVG Volume (30 Days)
- HPH 647.1K
- IPSC 462.0K
- Earning Date
- HPH 01-01-0001
- IPSC 11-05-2024
- Dividend Yield
- HPH N/A
- IPSC N/A
- EPS Growth
- HPH N/A
- IPSC N/A
- EPS
- HPH N/A
- IPSC N/A
- Revenue
- HPH $286,996,105.00
- IPSC $2,684,000.00
- Revenue This Year
- HPH N/A
- IPSC $244.52
- Revenue Next Year
- HPH N/A
- IPSC $27.73
- P/E Ratio
- HPH N/A
- IPSC N/A
- Revenue Growth
- HPH N/A
- IPSC 7.88
- 52 Week Low
- HPH $0.26
- IPSC $1.14
- 52 Week High
- HPH $10.06
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- HPH 30.33
- IPSC 37.50
- Support Level
- HPH $0.26
- IPSC $1.14
- Resistance Level
- HPH $0.38
- IPSC $1.50
- Average True Range (ATR)
- HPH 0.05
- IPSC 0.14
- MACD
- HPH 0.02
- IPSC -0.00
- Stochastic Oscillator
- HPH 24.70
- IPSC 18.65
About HPH HIGHEST PERFORMANCE HLDGS INC
Highest Performances Holdings Inc is a financial technology service group based on family financial asset allocation. It focuses on providing personalized wealth management services for emerging middle-class and affluent families, comprehensive support services for financial planners, and diversified financial services for institutional clients.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.